Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients ...
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. “We are pleased to present our initial clinical findings for CLN-619 plus pembrolizumab in patients with solid tumors at ASCO 2024, along with updated results from our monotherapy dose escalation study. CLN-619 is a novel, potential first-in-class antibody that binds to MICA and MICB stress-induced ligands that engage the activating r
Show less
Read more
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerGlobeNewswire
- Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? [Yahoo! Finance]Yahoo! Finance
- EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target raised by analysts at Jonestrading from $22.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
CGEM
Earnings
- 3/14/24 - Beat
CGEM
Sec Filings
- 4/30/24 - Form 4
- 4/30/24 - Form 3
- 4/29/24 - Form 8-K
- CGEM's page on the SEC website